Syncromune, a privately held, clinical-stage biopharmaceutical company, has secured $131,800,000 in funding from investors. This significant capital infusion will support the company's mission to develop SYNC-T, a potentially first-in-class platform immunotherapy designed to address major unmet needs and treatment challenges of incurable metastatic solid tumor cancers. Syncromune is focused on an innovative approach to cancer therapy through its proprietary technology.
SYNC-T is an in situ personalized cancer therapy engineered to synchronize the location of tumor antigens, immune cells, and a multi-target biologic drug. The treatment utilizes a novel proprietary device delivery system that first lyses a portion of a target tumor to release antigens, then facilitates the infusion of Syncromune's proprietary multi-target biologic drug directly into the tumor. This process aims to activate T cells, empowering the immune system to recognize and attack the patient’s cancer throughout the body. The company's lead candidate, SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer (mCRPC), is currently being evaluated in a U.S., multicenter, Phase 2a trial, known as LEGION-100.
The $131.8 million raised underscores investor confidence in Syncromune's novel therapeutic approach and its potential to impact cancer treatment. This funding round is crucial for a clinical-stage biopharmaceutical company, providing essential resources to progress its pipeline. The capital will be directed towards accelerating the development of the SYNC-T platform, specifically supporting the ongoing Phase 2a trial for SV-102 and other research and development initiatives.
With this substantial investment, Syncromune is poised to advance its innovative immunotherapy platform, aiming to bring new treatment options to patients battling advanced cancers. The company's continued progress in clinical development will be vital in evaluating the efficacy of its synchronized approach to harnessing the immune system against metastatic solid tumors.
